University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title

Cupid 2b: Enzyme Replacement Therapy for Advanced Heart Failure


A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure.  The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.

Please refer to identifier NCT01643330

 for more information.

Start Date
November 1, 2012
End Date
January 31, 2015
Gender Preference
Age Group
0 - 80 years
Principal Investigator
Frances Johnson, MD
Contact Info

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure (CUPID-2b)

Cardiomyopathy Treatment Program

Cynthia Larew, RN BSN

phone:   319-356-1028

fax:  319-356-7087


Department or Field of Study
cardiomyopathy ; CHF ; congestive heart failure ; Enter keyword ; gene therapy ; heart ; heart disease ; heart failure ; left ventricular failure ; undefined ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.